Prof. Coimbra’s High-Dose Vitamin D Therapy for Autoimmune Diseases

You can read the full article
here
.
Front. Immunol., April 7, 2021 | https://doi.org/10.3389/fimmu.2021.655739
Vitamin D Resistance as a Possible Cause of Autoimmune Diseases: A Hypothesis Confirmed by a Therapeutic High-Dose Vitamin D Protocol
- 1Dr. Beatrix Schweiger’s Practice, Bensheim, Germany
- 2Department of Radiotherapy and Radiation Oncology, Leopoldina Hospital Schweinfurt, Schweinfurt, Germany
- 3Dr. Beatrix Schweiger’s Practice, Waldkirch, Germany
- 4Academy for Human Medicine and Evolutionary Health, Schlangenbad, Germany
Vitamin D3 (cholecalciferol) is a secosteroid and prohormone which is metabolized in various tissues to the biologically most active vitamin D hormone 1,25(OH)2D3 (calcitriol). 1,25(OH)
The necessity of high doses of vitamin D3 for treatment success can be explained by the concept of an acquired form of vitamin D resistance. Its etiology is based on the one hand on polymorphisms within genes affecting the vitamin D system, causing susceptibility towards developing low vitamin D responsiveness and autoimmune diseases; on the other hand it is based on a blockade of vitamin D receptor signaling, e.g. through pathogen infections. In this paper, we review observational and mechanistic evidence for the acquired vitamin D resistance hypothesis.
We particularly focus on its clinical confirmation from our experience of treating multiple sclerosis patients with the so-called Coimbra protocol, in which daily doses up to 1000 I.U. vitamin D3 per kg body weight can be administered safely. Parathyroid hormone levels in serum thereby provide the key information for finding the right dose. We argue that acquired vitamin D resistance provides a plausible pathomechanism for the development of autoimmune diseases, which could be treated using high-dose vitamin D3 therapy.
For a consultation regarding high-dose vitamin D therapy according to Prof. Coimbra, please contact us
here.
Dirk Lemke1*‡,